| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer
1 company
Huntsman Carole serves as a Chief Commercial Officer at MDGL. Across recent SEC filings that breaks down to 0 buys and 23 sells. Those positions are worth an estimated $5.5M at current prices.
Historically, Huntsman Carole's trades have earned a below-average insider score of 32/100 across 5 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -49.6%.
The biggest single holding is MDGL (~$5.5M) as Chief Commercial Officer. The recent filings there lean toward selling, a net 5,246 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | Chief Commercial Officer | Sell | 419 | $431.94 | $180,982.86 | -3.2% | +11.1% | - | |
| Nov 21, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Chief Commercial Officer | Sell | 1,958 | $553.11 | $1,082,986.25 | -16.3% | -20.3% | - | |
| Mar 3, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Chief Commercial Officer | Sell | 1,834 | $325.98 | $597,839.68 | -17.6% | -13.0% | +35.9% | |
| Jan 24, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Chief Commercial Officer | Sell | 347 | $335.24 | $116,328.28 | -3.2% | -2.5% | +46.4% | |
| Nov 21, 2024 | MDGL Madrigal Pharmaceuticals, Inc. | Chief Commercial Officer | Sell | 688 | $316.92 | $218,040.96 | -6.0% | +4.4% | +66.4% |